Phase I, open-label, dose-escalation, safety and PK study of AZD6918

Study identifier:D2785C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients with Refractory Solid Malignancies

Medical condition

cancer,

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD6918, gemcitabine, pemetrexed

Sex

All

Actual Enrollment

75

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Aug 2008
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Mar 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria